Evidence map›Paper›PMID 41580512›Full record

ArticleCommunications biology2026

Development of capsaicin-derived prohibitin ligands to modulate the Aurora kinase A/PHB2 interaction and mitophagy in cancer cells.

Amel Djehal, Claire Caron, Deborah Giordano, Valentina Pizza, Kimberley Farin, Angelo Facchiano, Laurent Désaubry, Giulia Bertolin

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amel Djehal *Higher National School of Biotechnology of Constantine, Constantine, 25100, Algeria.
Claire Caron *CNRS, Univ Rennes, IGDR [(Institut de Génétique et Développement de Rennes)] - UMR 6290, Rennes, F-35000, France.ORCID http://orcid.org/0009-0007-3069-6108
Deborah GiordanoNational Research Council, Institute of Food Science, Avellino, 83100, Italy.
Valentina PizzaCNRS, Univ Rennes, IGDR [(Institut de Génétique et Développement de Rennes)] - UMR 6290, Rennes, F-35000, France.
Kimberley FarinRegenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, Strasbourg, 67084, France.
Angelo FacchianoNational Research Council, Institute of Food Science, Avellino, 83100, Italy.ORCID http://orcid.org/0000-0002-7077-4912
Laurent DésaubryRegenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, Strasbourg, 67084, France. desaubry@unistra.fr.ORCID http://orcid.org/0000-0002-1192-2970
Giulia BertolinCNRS, Univ Rennes, IGDR [(Institut de Génétique et Développement de Rennes)] - UMR 6290, Rennes, F-35000, France. giulia.bertolin@univ-rennes.fr.ORCID http://orcid.org/0000-0002-7359-5733

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aurora kinase A/AURKA is a serine/threonine kinase frequently overexpressed in cancer. Recent discoveries pointed to subcellular pools of AURKA, including at mitochondria. There, AURKA induces organelle clearance by mitophagy together with the autophagy mediator LC3, and its receptor PHB2.Here, we show that the natural product capsaicin modifies the AURKA/PHB2 interaction. We synthesize 16 capsaicin analogs, and Förster's Resonance Energy Transfer/Fluorescence Lifetime Imaging Microscopy (FRET/FLIM) in breast cancer cells reveals that compounds 12 and 13 increase the AURKA/PHB2 interaction. Molecular docking shows that they bind to the inhibitory pocket of PHB2 and to the AURKA active site. We demonstrate that compound 13 specifically inhibits mitophagy while leaving AURKA activation unaltered at centrosomes. Our results demonstrate that compound 13 is a PHB ligand acting on the AURKA/PHB2 interaction. Thanks to its specificity, it may lead to the development of anticancer drugs targeting the mitochondrial functions of AURKA.

Identifiers

PMID41580512
PMCPMC12936169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.